logo

Financials

Navigation Toggle
v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jul. 31, 2025
Apr. 30, 2025
Current assets:    
Cash and cash equivalents $ 13,178,305 $ 15,172,163
Marketable equity securities 261,853 366,316
Warrant asset – TNF - current 820,000 2,917,000
Convertible Note receivable – Femasys - current 4,608,000 3,696,000
Prepaid expenses and other current assets 238,180 223,759
Total current assets 19,106,338 22,375,238
Other assets:    
Intangible asset 1,549,427 1,549,427
Investment in preferred stock – TNF 19,635,000 22,474,000
Warrant asset – TNF - non current 2,966,000 5,701,000
Warrant asset – Femasys 1,846,000 3,061,000
Other assets 7,688 7,688
Total other assets 26,004,115 32,793,115
Total Assets 45,110,453 55,168,353
Current liabilities:    
Accounts payable 465,209 399,204
Accrued expenses 595,656 2,515,080
Total current liabilities 1,060,865 2,914,284
Other liabilities:    
Long-term portion of accrued expenses 0 25,000
Warrant liabilities 458,000 338,000
Total other liabilities 458,000 363,000
Total Liabilities 1,518,865 3,277,284
Commitments and Contingencies (Note 8)
Stockholders' equity:    
Common stock: authorized 200,000,000 shares, $0.0001 par value; 21,672,095 shares issued and 6,795,779 shares outstanding as of July 31, 2025 and April 30, 2025, respectively. 2,167 2,167
Additional paid-in capital 181,550,139 181,489,647
Accumulated deficit (93,329,056) (84,968,960)
Treasury stock, at cost, 14,876,316 shares as of July 31, 2025, and April 30, 2025, respectively (44,607,916) (44,607,916)
Accumulated other comprehensive loss (23,746) (23,869)
Total stockholders' equity 43,591,588 51,891,069
Total Liabilities, Convertible Preferred Stock and Stockholders' Equity 45,110,453 55,168,353
Series B Preferred Stock [Member]    
Convertible Preferred Stock:    
Convertible preferred stock 0 0
Series A Preferred Stock [Member]    
Stockholders' equity:    
Preferred stock value $ 0 $ 0

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
 3 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses:    
Research and development costs 95,157 96,016
General and administrative 753,148 1,172,871
Total operating expenses 848,305 1,268,887
Loss from operations (848,305) (1,268,887)
Other income (expenses):    
Interest income 217,793 547,432
Change in fair value of warrant liabilities 243,000 2,084,000
Change in fair value of derivative liability 0 1,204,000
Change in fair value of convertible note receivable - Femasys 912,000 245,000
Change in fair value of warrant asset - Femasys (1,215,000) (1,510,000)
Change in fair value of investment - TNF (2,839,000) 966,950
Change in fair value of warrants - TNF (4,832,000) (242,684)
Gain on legal settlement - re-fair value of warrants 106,000 0
Gain on related party investment - TNF 0 21,395,734
Unrealized loss on marketable securities (104,463) 0
Other expense (121) (190)
Total other income (loss), net (7,511,791) 24,690,242
Net income (loss) (8,360,096) 23,421,355
Preferred stock dividends 0 (685,801)
Preferred stock accretion 0 (2,148,047)
Net income (loss) attributable to common stockholders $ (8,360,096) $ 20,587,507
Basic income (loss) per share attributable to common stockholders $ (1.23) $ 1.90
Diluted income (loss) per share attributable to common stockholders $ (1.23) $ 1.90
Weighted average shares outstanding basic 6,795,779 7,866,387
Weighted average shares outstanding diluted 6,795,779 7,866,387

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 3 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Cash flows from operating activities:    
Net income (loss) $ (8,360,096) $ 23,421,355
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Gain on related party investment – TNF 0 (21,395,734)
Adjustment from accrued liabilities to warrant liabilities (469,000) 0
Gain on re-fair value of warrants (106,000) 0
Stock-based compensation 60,492 222,677
Unrealized loss on marketable equity securities 104,463 0
Change in fair value of warrant liabilities (243,000) (2,084,000)
Change in fair value of derivative liability 0 (1,204,000)
Change in fair value of convertible note receivable - Femasys (912,000) (245,000)
Change in fair value of warrant asset – Femasys 1,215,000 1,510,000
Change in fair value of investment – TNF 2,839,000 (966,950)
Change in fair value of warrants - TNF 4,832,000 242,684
Change in assets and liabilities:    
(Increase) decrease in prepaid expenses and other current assets (14,421) 19,573
Increase in accounts payable 66,005 164,582
Decrease in accrued expenses (1,006,424) (58,484)
Net cash and cash equivalents used in operating activities (1,993,981) (373,297)
Cash flows from investing activities:    
Investment in preferred stock and warrants 0 (7,000,000)
Net cash and cash equivalents used in investing activities 0 (7,000,000)
Cash flows from financing activities:    
Repurchase of common stock, net 0 (742,179)
Redemption of preferred stock 0 (9,429,583)
Net cash and cash equivalents used in financing activities 0 (10,171,762)
Effect of currency rate exchange on cash and cash equivalents 123 183
Net decrease in cash and cash equivalents (1,993,858) (17,544,876)
Cash and cash equivalents at beginning of the period 15,172,163 50,179,968
Cash and cash equivalents at end of the period 13,178,305 32,635,092
Supplemental disclosure of cash flows information:    
Cash paid during the periods for income taxes
Cash paid during the periods for interest
Supplemental disclosure of non-cash investing and financing activities:    
Reclassification of Series B Convertible Preferred Stock and dividends to current liability 0 9,367,750
Accretion of discounts to redemption value of Series B Preferred Stock 0 2,148,047
Excise tax accrued on repurchase of common stock $ 0 $ 7,421

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL